Showing session: reset
New Drugs on the Horizon 1
- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
Cochair
Melissa M. Vasbinder
Ribon Therapeutics, Inc., Lexington, MA, United States
- Permission not
granted for presentation
The discovery and preclinical characterization of AMG 176: A first-in-class Mcl-1 inhibitor in clinical development for multiple myeloma
Paul E. Hughes
Amgen, Inc., Thousand Oaks, CA, United States
- Free
- slides video
- audio + slides
- All slides included
AZD5991: A potent and selective macrocyclic inhibitor of Mcl-1 for treatment of hematologic cancers
Alexander W Hird
AstraZeneca, Waltham, MA, United States
- Permission not
granted for presentation
ABBV-621: A best-in-class TRAIL-receptor agonist fusion protein that enhances optimal clustering for the treatment of solid and hematologic tumors
Susan E. Morgan-Lappe
AbbVie, North Chicago, IL, United States
- Free
- slides video
- audio + slides
- All slides included
Discovery and development of H3B-6545: A novel, oral, selective estrogen receptor covalent antagonist (SERCA) for the treatment of breast cancer
Peter G. Smith
H3 Biomedicine Inc., Cambridge, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Durable efficacy and anticancer immunity following intratumoral administration of a combination of messenger RNAs encoding the costimulatory molecule OX40L and the cytokines IL-36g and IL-23
Josh P. Frederick
Onkaido, Cambridge, MA, United States